ISSN: 1301-2193 E-ISSN: 1308-9846
  • Turkish Journal of
    Endocrinology and Metabolism
ORIGINAL ARTICLE

Beneficial Effects of Fenofibrate on Lipoprotein (A) And Fibrinogen in Metabolically Well-Controlled Type 2 Diabetic Patients with Hyperlipidemia - Original Article
Beneficial Effects of Fenofibrate on Lipoprotein (A) And Fibrinogen in Metabolically Well-Controlled Type 2 Diabetic Patients with Hyperlipidemia - Original Article
Makale Dili: EN
ABSTRACT

Coronary heart disease (CHD) is the most common cause of death in patients with type 2 diabetes. The presence of well-estab1ished risk factors only partially explains the increased risk of CHD in diabetic patients. Twenty-three type 2 diabetic patients [16 female. 7 male; mean (±SD) age 56.6±11.0 years] with hyperlipidemia were evaluated before and and after 3 months of single dose of fenofibrate 250 mg (Lipofen® SR) treatment for atherogenic profile. Ali patients were under tight metabolic control for at least 3 months before the treatment. Total cholesterol, triglycerides, LDL-cholesterol, apolipoprolein B, Lp(a) fibrinogen levels were significantly decreased after 3 monîhs of treatment by 19.7%, 34.1%, 17.0%, 20%, 12%, 12% respectively (p<0.01). HDL-cholesterol and apolipoprotein A1 levels were significantly increased by 13.2%, 13.9% respectively (p<0.05). There was no significant change in HbA1c level during treatment (p>0.05). This short-term study showed no significant side effect of fenofibrate. in conclusion our study has shown the short term efficacy of micronised fenofibrate in hyperlipidemic patients with type 2 diabetes mellitus. Our data indicate that this drug is safe and efficacious in changing the atherogenic profile. Its beneficial effect is not only on classical lipid paramelers, but also on Lp(a) and fibrinogen as well.
Keywords: Type 2 diabetes, fenofibrate, lipoprotein (a), fibrinogen

ÖZET

Coronary heart disease (CHD) is the most common cause of death in patients with type 2 diabetes. The presence of well-estab1ished risk factors only partially explains the increased risk of CHD in diabetic patients. Twenty-three type 2 diabetic patients [16 female. 7 male; mean (±SD) age 56.6±11.0 years] with hyperlipidemia were evaluated before and and after 3 months of single dose of fenofibrate 250 mg (Lipofen® SR) treatment for atherogenic profile. Ali patients were under tight metabolic control for at least 3 months before the treatment. Total cholesterol, triglycerides, LDL-cholesterol, apolipoprolein B, Lp(a) fibrinogen levels were significantly decreased after 3 monîhs of treatment by 19.7%, 34.1%, 17.0%, 20%, 12%, 12% respectively (p<0.01). HDL-cholesterol and apolipoprotein A1 levels were significantly increased by 13.2%, 13.9% respectively (p<0.05). There was no significant change in HbA1c level during treatment (p>0.05). This short-term study showed no significant side effect of fenofibrate. in conclusion our study has shown the short term efficacy of micronised fenofibrate in hyperlipidemic patients with type 2 diabetes mellitus. Our data indicate that this drug is safe and efficacious in changing the atherogenic profile. Its beneficial effect is not only on classical lipid paramelers, but also on Lp(a) and fibrinogen as well.
Keywords: Type 2 diabetes, fenofibrate, lipoprotein (a), fibrinogen